| NEUROCRINE BIOSCI. DL-001 |
| USA |
| Gesundheit |
| US64125C1099 / 900964 |
| NB3 (Frankfurt) / NBIX (NASDAQ) |
| FRA:NB3, ETR:NB3, NB3:GR, NASDAQ:NBIX |
| - |
| http://www.neurocrine.com.. |
|
Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for mo..
>Volltext.. |
| 13624.13 Mio. EUR |
| 13634.64 Mio. EUR |
| 2905.47 Mio. EUR |
| 735 Mio. EUR |
| 607.55 Mio. EUR |
| 6.07 EUR |
| 346.01 Mio. EUR |
| 286.25 Mio. EUR |
| 723.12 Mio. EUR |
| 0.45 |
| 38.65% |
| 108.93% |
| - |
| - |
| - |
| - |
| NEUROCRINE |
| 11.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|